Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
← catalyst calendarNCT06207370 · readout in 194 d
Sponsored by 60 Degrees Pharmaceuticals LLC (industry) · SXTP — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
33estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-17 | actual | When the study began enrolling |
| Primary completion | 2027-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Babesiosis
Interventions
- Drug: Tafenoquine
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to sustained clinical resolution
measured Day 1 to 90
Permalink · SXTP's whole pipeline · Catalyst calendar · Every registered study · What changed